Description (Description)
The text is not-available.*
Venlafaxine Hydrochloride Capsule, Extended Release
Product Images NDC 80425-0290
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 80425-0290). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Advanced Rx Pharmacy Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Label 1 (Venlafazine HCl Er 80425 0290 01)
This is a medication called Venlafaxine HCL ER 37.5mg capsule. The package comes with 30 capsules and the National Drug Code (NDC) is 0425-0250:01. The source NDC is 42806-0601-09. There is a lot number mentioned as o0 with an expiry date of 3/23/3031. The numbers next to the lot number could be a serial number.*
Label 2 (Venlafazine HCl Er 80425 0290 02)
Label 3 (Venlafazine HCl Er 80425 0290 03)
This is a description of a medication package containing 90 capsules of Venlafaxine HCL ER with a strength of 37.5mg. The expiration date is indicated as 3723/3033.*
Fig 1 (Fig 1)
This text appears to be a list of drug interactions with certain medications, particularly CYP2D6 and CYP206 enzymes. The listed drugs include ethanol, diazepam, cimetidine, ketoconazole, indinavir, imipramine, lithium, and venlafaxine. Some drugs are recommended to avoid concomitant use, while others suggest using with caution or no dose adjustment. Clinical significance is unknown for some of the drugs. There is also a reference to PK Fold Change and 90% Cl Recommendation related to Cmax, and a number sequence listed under "Change relative to the reference value".*
Fig 2 (Fig 2)
This appears to be a list of drugs and their potential interactions or effects on the body, as well as their recommended dosages or precautions. However, without more context, it is difficult to determine its specific purpose or audience.*
Fig 3 (Fig 3)
This is a list of special populations with varying degrees of hepatic and renal impairments, CYP206 polymorphism, age, and gender that may affect the metabolism of specific analytes such as enlafaxine, enlataxine, and eniataine. The fold change and 90% CI are provided, along with recommendations for dose adjustments or individualization of dosing.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
